People Living With HIV

Since its establishment in 1987, thousands of people living with HIV have participated in clinical trials at the Case ACTU. Their participation led directly to the development of effective and better treatments for HIV infection. Many of the clinical trials offered at the Case ACTU are through its affiliation with the AIDS Clinical Trials Group (www.actgnetwork.org). At any given point in time, the Case ACTU has several trials enrolling HIV-positive people for a variety of new medicines and treatments.

To receive more information or for questions regarding AIDS clinical trials at Cleveland Medical Center, call Jane Baum at 216-844-2546 or email [email protected]

 


Title: A5391: Doravirine for Persons with Excessive Weight Gain while taking Integrase Inhibitors and Tenofovir Alafenamide (TAF): The DO-IT Study Click here for printable participant summary. Description: Weight gain after starting anti-HIV medicines is common, but recent studies have found that taking certain medicines may cause increased weight more than […]

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase ...


Title: A5386: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control in the Reservoirs During Analytic Treatment Interruption Purpose: Researchers are looking for ways to get rid of HIV that rests hidden in areas of the body (reservoirs) where current […]

A5386, a clinical trial to control HIV in a new ...



Title: A5379 BEEHIVE B-Enhancement of HBV Vaccination in Persons Living with HIV (BEe-HIVe) Description Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. Although there is a vaccination for hepatitis B, sometimes the vaccines do not work well for people […]

A5379: BEEHIVE, a Hepatitis-B Vaccine Study for People Living with ...


Protocol Summary: Trio (ACTG5377) is a Phase I, first-in-human, ascending-dose study of a tri-specific broadly neutralizing antibody, in participants living with HIV. This trial will look at a human-made antibody called SAR441236. Unlike the antibodies created by a person’s immune system that attach to HIV at one part, SAR441236 has […]

Trio A5377: A Phase I, first-in-human, ascending-dose study of a ...



Protocol Summary: This study will compare the use of long-acting, injectable anti-HIV medicines with anti-HIV medicines in daily pill form for people living with HIV who have not been previously adherent (keeping up) with their anti-HIV medicines in daily pill form. Purpose of This Study: Anti-HIV medicines taken as pills […]

Latitude A5359: To see if long-acting, injectable ARTs are helpful ...